Jubilant Pharmova's financial performance is mixed. Sales have grown consistently, but profit growth has been volatile. The OPM % has fluctuated, reflecting inconsistent operational efficiency. While compounded sales growth demonstrates a positive trend, the compounded profit growth has been inconsistent.

Quarterly sales have generally increased, however, the operating profit margin has seen some fluctuations. Other income has varied, significantly affecting the profit before tax. The company needs to stabilize its profit growth and enhance operational efficiency.

Capital efficiency and returns on equity for Jubilant Pharmova show concerning trends. ROCE and ROE were healthy in prior years but have declined significantly, indicating a weakened ability to generate returns from capital and shareholder funds.

| Metric | 2014-2016 | 2017-2019 | 2020-2022 | 2023 | 2024 | 2025 | |---|---|---|---|---|---| | ROCE (%) | 10 | 15.33 | 12.33 | 3 | 7 | 10 |

The decline in ROCE and ROE raises concerns about the company's ability to efficiently allocate capital and generate shareholder value.

Jubilant Pharmova's financial health and prudence require careful consideration. The company's debt management reveals fluctuating borrowings over the years. The dividend payout has been inconsistent.

| Metric | 2014-2016 | 2017-2019 | 2020-2022 | 2023 | 2024 | 2025 | |---|---|---|---|---|---| | Borrowings | 4563 | 3951 | 3609 | 3677 | 3664 | 2731 |

While borrowings have decreased in the most recent year, the overall trend shows variability. The absence of a consistent dividend payout policy may affect investor sentiment. These factors suggest the need for vigilant financial management.

The shareholding and ownership structure of Jubilant Pharmova present a mixed picture. Promoter holding remains stable, indicating continued alignment with the company's vision. However, there has been a decrease in FII holding, offset by an increase in DII holding.

This shift in institutional holding patterns may reflect changing investor sentiment or strategic decisions by these entities.

The quarterly results of Jubilant Pharmova show significant volatility in net profit. There are fluctuations in quarterly sales growth, operating profit, and net profit.

This variability indicates potential inconsistencies in segment performance, which could impact overall financial stability.

Jubilant Pharmova has exposure to interest rate fluctuations, as evidenced by the interest expenses reported quarterly.

The increasing interest expenses indicate a potential risk due to rising interest rates, which could affect profitability.

The expenses have been increasing every year which implies that regulatory compliance cost trends are also increasing every year.

| Year | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |---|---|---|---|---|---|---|---|---|---|---|---| | Expenses | 4,763 | 5,141 | 4,493 | 4,510 | 5,995 | 7,367 | 4,428 | 4,695 | 4,980 | 5,503 | 5,802 | 6,061 |